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The lack of functional understanding of most muta-
tions in cancer, combined with the non-druggability
of most proteins, challenge genomics-based identifi-
cation of oncology drug targets. We implemented a
machine-learning-based approach (idTRAX), which
relates cell-based screening of small-molecule com-
pounds to their kinase inhibition data, to directly
identify effective and readily druggable targets. We
applied idTRAX to triple-negative breast cancer cell
lines and efficiently identified cancer-selective tar-
gets. For example, we found that inhibiting AKT
selectively kills MFM-223 and CAL148 cells, while in-
hibiting FGFR2 only kills MFM-223. Since the effects
of catalytically inhibiting a protein can diverge from
those of reducing its levels, targets identified by id-
TRAX frequently differ from those identified through
gene knockout/knockdown methods. This is critical
if the purpose is to identify targets specifically for
small-molecule drug development, whereby idTRAX
may produce fewer false-positives. The rapid nature
of the approach suggests that it may be applicable in
personalizing therapy.
INTRODUCTION
Kinases are regarded as attractive drug targets for neoplastic
diseases because of their pivotal role in signal transduction
and regulation of most cellular activities, frequent activation in
cancers, and inherent tractability for small-molecule drug ap-
proaches. Consequently, small-molecule kinase inhibitors have
gained tremendous attention in cancer drug discovery in the
past two decades. The US Food and Drug Administration
(FDA) approval of a BCR-ABL1 inhibitor imatinib (Gleevec,
Novartis) against chronic myeloid leukemia in 2001 served asCthe first confirmation that targeting kinases with small molecules
is a viable therapeutic approach. Currently, 130 out of 518 enzy-
matically active human protein kinases have been proposed as
potential therapeutic targets (Rask-Andersen et al., 2014). To
date, 55 small-molecule kinase inhibitors have been approved
for therapeutic use, and around 250 are being investigated for
clinical use (Wu et al., 2015, 2016; Yang et al., 2016; Klaeger
et al., 2017).
Even though extensive studies have been carried out to
target the human kinome, they are mostly limited to a small
subset of human kinases, typically to tyrosine kinases (TK).
The kinome contains six additional kinase classes, namely
tyrosine kinase-like (TKL); homologs of yeast sterile 7, sterile
11, sterile 20 kinase (STE); casein kinase; containing protein ki-
nase A, G, and C families; calcium/calmodulin-dependent pro-
tein kinase; containing CDK, MAPK, GSK3, and CLK families
(CMGC) and a few atypical kinases, including the phosphatidy-
linositol 3-kinase (PI3K) family of lipid and protein kinases. The
vast majority of approved kinase inhibitors target TK and only a
few approved inhibitors target kinases, including BRAF from
TKL, MEK1/2 from STE, CDK4/6 from CMGC and PI3Ka,
and PI3Kd and mammalian target of rapamycin (mTOR)
from PI3K. This highlights the opportunity to explore kinases
of other classes as potential anti-cancer targets. With the
availability of the Published Kinase Inhibitor Set (PKIS)
from GlaxoSmithKline (GSK), it has been possible to explore
the kinases of other classes as well (Knapp et al., 2013; Drewry
et al., 2014, 2017). PKIS has broad kinome coverage going
beyond TKs where the activities of the compounds are
assayed against 224 kinases including 23 disease-related
mutant kinases (Elkins et al., 2016).
Six small-molecule kinase inhibitors, namely lapatinib,
neratinib (HER2 inhibitors) palbociclib, ribociclib, abemaciclib
(CDK4/6 inhibitors), and everolimus (mTOR inhibitor) have
received accelerated FDA approval due to their efficacy against
advanced stage breast cancer (Schwartzberg et al., 2010; Sher-
rill et al., 2010; Katsumi et al., 1989; Beck et al., 2014). Lapatinib
(Tykerb, GSK) and neratinib (Nerlynx, Puma Biotechnology) were
approved for HER2-positive metastatic breast cancer andell Chemical Biology 26, 1–10, July 18, 2019 ª 2019 Elsevier Ltd. 1
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for hormone receptor-positive, HER2-negative breast cancer.
Triple-negative breast cancer (TNBC), devoid of hormone recep-
tors and HER2, remains a clinical challenge with no approved
targeted therapies except for the PARP inhibitor olaparib for
BRCAmutantmetastatic TNBC. TNBC is a highly heterogeneous
and aggressive group of cancers that accounts for 15%–20% of
breast cancer cases. Approximately 75% of all kinases are ex-
pected to be expressed in any given breast cancer cell (Manning
et al., 2002). The identification of cell context-specific kinase de-
pendencies therefore poses a great potential for establishing
therapeutic strategies against TNBC.
Most small-molecule kinase inhibitors target the highly
conserved ATP binding pocket of kinases, which results in vary-
ing degrees of target promiscuity (Anastassiadis et al., 2011).
Such target promiscuity can result in undesirable off-target ef-
fects. Sometimes, however, it may instead enhance the efficacy
by targeting compensatory, redundant, or synergistic therapeu-
tic pathways (polypharmacology) (Knight et al., 2010). Generally,
the promiscuity of kinase inhibitors makes it challenging to
pin-point the key target(s) through which an individual com-
pound exerts its phenotypic response.
Using a Machine-Learning Approach to Deconvolve Cell
Line-Selective Kinase Dependencies from Drug
Sensitivities
The genetic complexity of cancer, combinedwith poor functional
understanding of most cancer mutations, has made it difficult to
identify oncological drug targets based on mutational analyses
alone. This is further compounded by the fact that knocking
down a protein can yield effects that diverge from pharmacolog-
ically engaging it with a small molecule or biologic (Weiss et al.,
2007). Finally, most of the proteome is predicted to be undrug-
gable, which means that most potential drug targets identified
using genetic methods are challenging to translate to pharmaco-
logical drug development. We explored an approach that iden-
tifies effective and readily druggable targets in a more direct
manner, starting from a cellular model of disease (Al-Ali
et al., 2015).
The experimental-computational approach begins by
screening a highly annotated collection of kinase inhibitors in
the cell-based assay (476 inhibitors; see Figure 1), and then iden-
tifying the compounds that produce the desirable phenotype
(e.g., death of cancer cells), as well as compounds that produce
the undesirable phenotype (e.g., survival or proliferation of can-
cer cells). We used a machine-learning-based algorithm, that re-
lates the activity of compounds in the cell-based assay to their
kinase inhibition profiles, and identifies kinases whose inhibition
are likely to mediate the desirable phenotypic outcome (targets),
as well as kinases whose inhibition are likely to mediate the un-
desirable phenotypic outcome (anti-targets).
In this study, we applied our previously established approach
of combining machine-learning and information theory with cell-
based drug screening to identify such mechanistic kinase tar-
gets with anti-cancer potential (Al-Ali et al., 2015). We generated
selective kinase-dependency profiles for 19 breast cancer cell
lines covering the six major transcriptomic-based subtypes
(Lehmann et al., 2011).2 Cell Chemical Biology 26, 1–10, July 18, 2019RESULTS
TNBC Exhibits Diverse Kinase Dependencies
We applied idTRAX, an application of the method described in
Al-Ali et al., 2015 currently developed by Truvitech LLC, to 16
TNBC cell lines, in comparison with 3 non-TNBC cell lines.
TNBC can be subclassified into six subtypes based on transcrip-
tomic analysis; basal like 1, basal like 2, mesenchymal like,
mesenchymal stem like, immune-modulators, and luminal
androgen receptor (Lehmann et al., 2011) (Figure 2A). On per-
forming a clustering analysis of cell lines based on their kinase-
dependency profiles derived from idTRAX analysis, we found
that the kinase-dependency-based grouping of cell lines does
not match with the gene expression-based subtypes, similar to
what we have previously found with our broader compound
profiling (Gautam et al., 2016). This further highlights the need
for target identification and personalized medicine approaches
that address the disconnection between standard molecular
profiling methods and functional cellular responses of cancer
in general, and in TNBC in particular.
The idTRAX approach effectively captured known generic ki-
nase dependencies, such as mitotic kinase PLK1 and pivotal
lipid kinase PI3K essentiality for all the cell lines screened (Fig-
ure 2B, dark green boxes). In addition, we also identified well-es-
tablished cell line-selective kinase dependencies, for example
BRAF in DU4475, carrying an activating BRAF (V600E mutation).
Similarly, three cell lines, BT-474, SK-BR-3, and MDA-MB-453,
harboring HER2 amplification and overexpression, showed
markedly selective dependency toward the HER family of ki-
nases (EGFR, HER2, and ERBB4). Moreover, KRAS mutant
MDA-MB-231 cells exhibited dependency toward MAP2K1
and NTRK3 mutant MFM-223 cells dependency toward the
NTRK family. In addition, our algorithm predicted many cell
line-selective kinase dependencies which represent currently
understudied kinases that may have high therapeutic potential.
Examples of such cell line-selective dependencies include
FGFR2 in MFM-223, AKT in MFM223 and CAL-148, MELK in
CAL-85-1, MAPKAPK3 in MDA-MB-453, MAPK14 in CAL-85-
1, PI4KB in DU4475, SGK3 in CAL-120, and TSSK1B in HDQ-P1.
MFM-223 Is Selectively Addicted to FGFR2
To validate the idTRAX predictions, we tested a unique depen-
dency of FGFR2 predicted for MFM-223 cell line with pharmaco-
logical inhibition and gene-silencing techniques in comparison
with two other cell lines, CAL-120 and MDA-MB-231, which
had low FGFR family MAXIS*Bk scores (Figure 3A). For pharma-
cological validation, we tested well-known pan-FGFR inhibitors
erdafitinib, AZD4547 and lucitanib. As predicted, all three inhib-
itors exhibited strong selective viability inhibition on MFM-223,
with negligible effect on CAL-120 and MDA-MB-231 (Figure 3B).
We performed short interfering RNA (siRNA)-based knockdown
of the four FGFR isoforms (1–4) to confirm the FGFR2-specific
dependency toward MFM-223. FGFR2 silencing had significant
viability inhibiting effect, whereas silencing the other isoforms
had a negligible effect on viability of MFM-223 cells (Figure 3C).
The silencing of FGFR family genes had no effect on the viability
of CAL-120 and MDA-MB-231 cells (Figure 3C). Our findings
support a previous report showing association of FGFR2 with
the cellular toxicity of MFM-223 (Fink et al., 2015).
Figure 1. Illustration of the Kinase Dependency Deconvolution Approach
Cell line-selective kinase dependencies are predicted using a machine-learning algorithm (idTRAX) that maps the activity of compounds in the cell-based assay
(drug sensitivity score [DSS]) to their kinase inhibition profiles (target activity data).
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Besides FGFR2, we also tested AKT dependency across the cell
lines. We focused on two cell lines, MFM-223 and CAL-148, pre-
dicted to be dependent on AKT kinases, and two control celllines, CAL-120 and MDA-MB-231, predicted to be unaffected
with AKT inhibition (Figure 4A). Three AKT selective inhibitors
afuresertib, uprosertib, and ipatasertib were tested against the
cell lines. In line with the idTRAX predictions, AKT inhibition
resulted in strong reduction of the viability of MFM-223 andCell Chemical Biology 26, 1–10, July 18, 2019 3
A B
Figure 2. Breast Cancer Cell Lines Exhibit Diverse Kinase Dependency Patterns
(A) Table representing list of breast cancer cell lines used in the study, 16 TNBC cell lines along with 1 non-cancerous triple-negative (TN) epithelial cell line (MCF-
10A), and 2 HER2 (ERBB2)-amplified cell lines (SK-BR-3 and BT-474). The color of the cell line represents the transcriptomics-based TNBC subtypes (Lehmann
(legend continued on next page)
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Figure 3. FGFR2 Dependency in MFM-223
(A) Heatmap based onMAXIS*Bk score, predicting selective FGFR2 dependency inMFM-223 cell line. CAL-120 andMDA-MB-231were predicted to be resistant
to FGFR inhibition.
(B) Validation of FGFR dependency with three FGFR inhibitors; mean ± SEM, n = 3.
(C) Bar plot illustrating the effect of siRNA-based knockdown of four different FGFR isoforms in the three cell lines. One-way ANOVA, mean ± SEM, n = 5,
****p < 0.0001.
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MDA-MB-231 cell lines (Figure 4B). We also performed a gene
knockdown experiment with siRNA for the three AKT isoforms:
AKT1, AKT2, and AKT3. To our surprise, AKT gene knockdowns
did not reciprocate the effect seen with AKT inhibitors in the
MFM-223 cell line. This result suggests that a compound
screening approach yields more directly translatable result
than loss-of-expression screenings.et al., 2011) and non-TNBC cell lines are marked with black labels. BL1, basal lik
immune-modulators; LAR, luminal androgen receptor.
(B) Heatmap of kinase-dependency profile of the cell lines based on MAXIS*Bk s
color in the heatmap indicates that inhibition of that kinase results in anti-prolife
liferative effect. Generic and known cell line-selective kinase dependencies are hIn certain instances, kinase dependencies revealed through
gene silencing cannot be reproduced by pharmacological kinase
inhibition. For example, based on both siRNA and short hairpin
RNA (shRNA) screens (Campbell et al., 2016; Marcotte et al.,
2016) AURKA is selected as an essential kinase for maintaining
viability of MFM-223 cells. However, idTRAX analysis predicted
that AURKA inhibition has no effect on MFM-223 cells (Fig-
ure 5A). In validation experiments, the AURKA-selective inhibitore 1; BL2, basal like 2; M, mesenchymal like; MSL, mesenchymal stem like; IM,
core representing cell lines clustering horizontally and kinases vertically. Red
rative effect, whereas blue indicates that inhibition might lead to the pro-pro-
ighlighted as dark green boxes.
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Figure 4. Cell Line-Selective Sensitivity toward Catalytic Inhibition of AKT
(A) Heatmap based onMAXIS*Bk score, predicting selective AKT dependency inMFM-223 andCAL-148 cell lines. CAL-120 andMDA-MB-231were predicted to
be unaffected by AKT inhibition.
(B) Effect of three selective AKT inhibitors on the viability of the cell lines; mean ± SEM, n = 3.
(C) siRNA-based knockdown of three different AKT isoforms fails to validate susceptibility to AKT inhibition. One-way ANOVA, mean ± SEM, n = 5, ****p < 0.0001.
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iments (Figure 5B). However, knocking down AURKA using
siRNAs had strong viability inhibition effect on MFM-223 (Fig-
ure 5C). We further validated knockdown result using AURKA
siRNAs from two different companies, Ambion and QIAGEN,
and both caused marked inhibition of MFM-223 cell viability.
This result highlights the relevance of our approach to identifying
and developing pharmacological drug targets.
Discordance within Kinase-Dependency Profiles
Generated by Different Gene-Silencing Approaches
and idTRAX
To further explore the observed discordance between the cell
line-selective kinase dependencies acquired from kinase6 Cell Chemical Biology 26, 1–10, July 18, 2019silencing and pharmacological inhibition, we conducted a sys-
tematic comparison of kinase-dependency profiles obtained
from complementary functional genomics screening ap-
proaches with our kinase-specific dependency estimates
derived from idTRAX analysis from kinase inhibitor sensitivity
screens. Specifically, we obtained kinase-dependency scores
for breast cancer cell lines from a high-throughput siRNA
screening performed by Campbell et al. (2016). Further, we ob-
tained kinase-dependency scores based on genome-wide
shRNA screen, performed by Marcotte et al. (2016), for overlap-
ping sets of kinases in the breast cancer cell lines profiled in both
of the studies.
Strikingly, we did not observe much agreement between the
siRNA and shRNA screening datasets (average rank correlation
AB C
Figure 5. Cell Line-Selective Sensitivity to-
ward Transcriptional Knockdown and Phar-
macologic Inhibition of Aurora A
(A) Heatmap representing AURKA dependency on
MFM-223 based on two gene-silencing studies
(siRNA [Z score; Campbell et al., 2016] and
shRNA [z-GARP score; Marcotte et al., 2016]) and
pharmacological inhibition prediction based on
MAXIS*Bk score.
(B) Dose-response curve of AURKA-selective
inhibitor alisertib against MFM-223; mean ± SEM,
n = 4.
(C) Effect on viability of MFM-223 with siRNA-based
knockdown of AURKA. siRNAs from two different
companies QIAGEN (Q) and Ambion (A) were used in
the study and both showed significant viability inhi-
bition. One-way ANOVA, mean ± SEM, n = 5,
****p < 0.0001.
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gible agreement between idTRAX-derived kinase dependency
scores with siRNA-based kinase-dependency scores (r = 0.04,
p = 0.068) or shRNA-based kinase-dependency scores
(r = 0.04, p = 0.02) (Figure 6A). Furthermore, comparison of
the kinase-dependency estimates obtained from genome-wide
CRISPR knockout screens (Meyers et al., 2017) with the other
scores also yielded poor correlation estimates, suggesting a
lack of agreement between these gene-silencing approaches.
Among the different gene-silencing methods, siRNA and
CRISPR data matched better (r = 0.19, p < 0.0001). These ob-
servations were more evident while focusing on data from one
cell line (MDA-MB-231) (Figure 6B). Based on these results,
none of the gene-silencing approaches as such could replicate
the cell line-selective kinase dependencies acquired from our
pharmacologically based idTRAX analysis.
DISCUSSION
Clinically investigated kinase inhibitors are limited to a small
group of kinase targets. A large number of kinases remain to
be explored for their usefulness as pharmacological targets of
small-molecule drugs. Inhibitor promiscuity is often observed
with kinase inhibitors, as most of them target the highly
conserved ATP binding pocket (Anastassiadis et al., 2011).
Such promiscuity can lead to detrimental off-target effects, but
it can—and sometimes does—lead to favorable therapeutic
outcome by targeting compensatory pathways (Knight et al.,
2010). Therefore, it is highly important to deconvolve the kinase
dependencies for the development of effective targeted thera-
pies and drug combination strategies. However, pinpointing
such specific kinase dependency is challenging, thereby
requiring computational approaches to identify cancer-selective
kinase dependencies. To address this issue, we developed a
more direct approach starting from cellular model of disease to
identify effective and readily druggable targets (Al-Ali et al.,
2015). We implemented our machine-learning algorithm idTRAX,
which integrates the activity of compounds in the cell-based
assay to their kinase inhibition target profiles, to identify thecell line-selective kinases whose inhibition mediates reduced
cell viability (desirable outcome) or increased cell proliferation
(undesirable outcome).
Our approach predicted many cell line-selective potential ki-
nase dependencies not described before, such as PI4KB in
DU4475, SGK3 in CAL-120, and TSSK1B in HDQ-P1. The sensi-
tivity of our approach was validated by its ability to identify well-
established kinase dependencies. Altogether, our study under-
scores the heterogeneity of kinase dependencies in TNBC,
therefore suggesting a more effective approach to tackle this
heterogeneous disease is a personalized medicine approach.
However, the power of predictability of idTRAX is limited by
the compound set used for the training and how well the inhibi-
tors can discriminate between different kinases. For that reason,
it is important to develop even better sets of well-profiled inhib-
itors with broader target ranges and higher level of selectivity and
it is promising that such efforts are moving ahead (Drewry et al.,
2017; Muller et al., 2018). We are also putting our efforts in
compilation of a high-quality consistent database for drug target
interaction which we call Drug Target Commons (https://
drugtargetcommons.fimm.fi) (Tang et al., 2018), this kind of
extensive dataset will definitely serve better for target deconvo-
lution approaches. With further optimization of compound col-
lections with greater diversity in terms of target spectra and
chemical backbones, the method can be further explored to
evaluate or predict the co-target dependencies and drug combi-
nations effective against cancer cells. In our previous study (Al-
Ali et al., 2015), we explored the approach to predict the additive
and synergistic kinase inhibitor combinations that leads to
enhanced neurite outgrowth compared with single inhibition. In
the study, we tested the hits (kinase dependencies), co-treated
them with inhibitors that have differing hit kinase inhibition pro-
files and distinct chemical structure, and thereby were able to
establish synergistic inhibitor combinations. Therefore, further
exploration of the method by co-targeting the cell model-selec-
tive kinase dependencies with inhibitors having unrelated chem-
ical structure and unique kinase inhibition profile holds the po-
tential to predict additive or synergistic drug combinations
against cancer cells.Cell Chemical Biology 26, 1–10, July 18, 2019 7
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Figure 6. Correlation between Kinase Dependencies Assimilated Using Different Screening Approaches (Drug, siRNA, shRNA, and CRISPR
Screening)
siRNA screening data (Z score), shRNA data (z-GARP scores) and CRISPR data (CERES score) were extracted fromCampbell et al. (2016), Marcotte et al. (2016),
and Meyers et al. (2017) studies, respectively. MAXIS*Bk score represents kinase-dependency profile based on compound screening. Only kinases common to
all datasets (n = 179) were used in the analysis.
(A) Dot plot comparing correlation (Spearman rank correlation) between different functional profiling approaches. For each comparison, only the cell lines that are
common between the two datasets were incorporated. Colors indicate individual cell lines. Horizontal lines with whiskers represent mean value ± 1 standard
deviation of all cell lines.
(B) Scatterplot comparing scores from different methods in a representative cell line MDA-MB-231. The points correspond to the common kinases between the
datasets used in the analysis. r = Spearman rank correlation.
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silencing of kinases, we saw great differences in responses. In
the case of the predicted AKT dependencies in MFM-223 and
CAL-148 cells, we could confirm that additional AKT inhibitors
strongly affected the viability of the cells, but siRNAs against indi-
vidual AKT isoforms had minimal effect on cell viability. This indi-
cates that theremay be redundancy between the AKT isoforms in
these cells, and that blockingmore than one isoform is needed to
reach the effect. Conversely, transcriptomic silencing of AURKA
had been reported to induce a strong inhibition effect on MFM-
223 cells, but we showed that selective kinase inhibition of
AURKA had no effect on MFM-223 cell viability, suggesting that
the sensitivity to AURKA knockdown is not strictly kinase depen-
dent, and highlighting that knockdown approaches often overes-
timate the effect of pharmacological inhibition of an enzyme.
Further analysis and comparison of the overall kinase depen-
dency predicted by idTRAX with those from published gene-
silencing screening approaches also yielded discordant results.
To our surprise,most kinase dependencies identified fromkinase
inhibition screens were not recapitulated in either RNAi or
CRISPR screens and vice versa. Most often, only generic depen-
dencies such as PLK1 or very strong oncogenic drivers such as
HER2 in HER2-amplified breast cancer cell lines matched
between the kinase inhibition and RNAi/CRISPR screens.
Taken together, our results show that it is challenging to identify
druggable targets with genomic or knockdown approaches only.
Although genome/kinome-wide knockout and knockdown
screening has helped us to appreciate the potential of kinases
as therapeutic targets, the findings emerging from such studies
have often been impossible to turn to drug targets, perhaps
because the hits that come out of these screens may not be pre-
dictable of the efficacy of pharmacological kinase inhibition. Our
data suggest that a chemogenomics-based target deconvolution
strategymay result in fewer false-positives thangenomics-based
approaches. Therefore, the type of approach we present holds
promise as an alternate method for identifying cancer drug tar-
gets that are readily tractable with pharmacological therapies.
SIGNIFICANCE
Functional target profiling, using a combination of chemical
probes, phenotypic screening, and machine learning might
fill a translational void that exists in omics and gene-editing
approaches. In this study, profiling a collection of kinase in-
hibitors in drug-sensitivity assays allowed us to directly and
efficiently identify cancer-selective drug targets. The rapid
and robust nature of the approach suggests that it will
have high utility for identifying the cancer-selective targets
that could be explored for precision therapy. The robustness
of the platform derives from the fact that it identifies targets
based on aggregated data from hundreds of compounds, as
opposed to other methods that test one gene at a time, mak-
ing themmore susceptible to noise and false-positive hits. In
this proof-of-principle study, we efficiently captured breast
cancer-selective pharmacological targets, which included
both previously known genetic driver kinases as well as
kinase dependencies that were not predicted as drivers by
genetic means. Applying this approach in the future to
ex vivo patient samples may better predict cancer-selectivedrug targets at an individual patient level, thereby consti-
tuting a valuable guide for development of precision medi-
cine approaches and rational design of therapies to suit
individual patients’ cancer vulnerabilities.
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Cell Lines
Human breast cancer cell lines used in this study are listed in Table S1. The cell lines were purchased fromATCC or DSMZ collections
and maintained in their respective culture medium at 37C with 5% CO2 in a humidified incubator, according to provider’s instruc-
tions. DMEM (Cat#12800-058), McCoy (Cat#M9309) and RPMI (Cat#12-167F) media were purchased from Life Technologies,
Sigma-Aldrich and Lonza respectively. The identity of all the cell lines used in this study were authenticated using the GenePrint
10 System (Promega) and were tested negative to be mycoplasma free. Mycoplasma test was based on the method
described by (Vojdani et al., 1998) and was performed as a service by the sample management laboratory of THL Biobank, Helsinki,
Finland.
METHOD DETAILS
Inhibitors
Two sets of kinase inhibitors were utilized in this study. The first was the Published Kinase Inhibitor Set (PKIS-1) consisting of 356
compounds (listed in Table S2), which was provided by GlaxoSmithKline (GSK) (Knapp et al., 2013; Drewry et al., 2014). These com-
pounds have previously been target annotated against 200 wild type kinases and 24 mutant kinase variants (Elkins et al., 2016). The
compounds were dissolved in DMSO and stored in pressurized Storage Pods (Roylan Developments Ltd.) filled with inert nitrogen
gas according to the manufacturer’s instructions.
Second, in-house drug sensitivity data for another set of compounds consisting of 116 kinase inhibitors that had previously target-
annotated the same way as the PKIS-1 set was utilized for the analysis ((Gautam et al., 2016; Anastassiadis et al., 2011) Table S3).
Beside those 116 kinase inhibitors, four more inhibitors were used in validation experiments, which included two FGFR inhibitors:
lucitanib and erdafitinib, and two AKT inhibitors: uprosertib and afuresertib. (Table S3, inhibitors used in validation experiments
are highlighted in yellow).
Drug Sensitivity and Resistance Testing
The drug screening and resistance testing platform that has been described previously (Gautam et al., 2016) was applied on the
breast cancer cell lines. The compounds were plated to white clear bottom 384-well plates (Corning #3712) in 5 concentrations in
10-fold dilution steps covering a 10,000-fold concentration range (1 nM to 10 mM for PKIS compounds) using an Echo 550 Liquid
Handler (Labcyte). Cell killing benzethonium chloride (BzCl, 100 mM) and compound vehicle dimethyl sulfoxide (DMSO, 0.1%)
were used as positive and negative controls, respectively. All subsequent liquid handling was performed using aMultiDrop dispenser
(Thermo Scientific). The pre-dispensed compounds were dissolved in 5 ml of culture media for 30 min at ambient temperature on an
orbital shaker. Twenty microliter cell suspension containing optimal number of cells respective to cell lines (defined in Table S1) per
well were seeded in the treatment plates. After 72 h incubation, 2.5 mL of viability measurement reagent CellTiter-Blue (Promega)
was dispensed in the plates. After incubation for 2 h at 37C, fluorescence was measured with a PHERAstar FS plate reader
(BMG Labtech). Each cell line was screened once.
The raw fluorescence data were analyzed in Breeze software, an in-house developed data analysis and management software, to
generate normalized (%cell viability inhibition) data points and dose-response curves. No data points were excluded for the analysis.
Drug sensitivity score (DSS), a modified area under the dose-response curve measure was calculated for each drug using the DSS-R
software package (https://sourceforge.net/projects/dss-calculation/) (Yadav et al., 2014). All DSS values are available in Table S5
and normalized drug screening data used to compute DSS are available in Table S6.
To validate the predicated druggable targets FGFR and AKT, three different compounds for each target (two of which were not
included in the target deconvolution analysis; FGFR inhibitors: lucitanib and erdafitinib, AKT inhibitors: uprosertib and afuresertib)
were tested (Figures 3 and 4, highlighted yellow in Table S3). The compounds were tested in 6 concentrations with 10-fold dilution
steps as described before with a slight modification. Each concentration point was tested in triplicate and cell viability wasmeasured
using CellTiter-Glo (Promega) after 72 h of incubation. The drug screening data were normalized to positive and negative controls
(BzCl and DMSO respectively) to generate % cell viability inhibition and subsequently mean± SME values were used to generate
dose response curves in GraphPad Prism.
siRNA Screening
Silencer Select siRNAs from Ambion were used for this study (Table S4). Kinase-targeting siRNAs along with scrambled non-target-
ing siRNAs and Allstars Hs Cell Death Control siRNAs (10 nM final concentration, Qiagen) were transferred to 384 well plates
(Corning #3712) with an Echo 550 Liquid Handler (Labcyte). Three different siRNAs against each target were pooled together in equal
concentrations to obtain final concentration of 10 nM (3.33 nMeach). 5 ml of Opti-MEM (Life Technologies, Cat# 31985070) containing
50 nl of Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) was added to each well of plates with pre-dispensed
siRNA using a MultiDrop Combi nl dispenser (Thermo Scientific) and incubated at ambient temperature for 20 min on an
orbital shaker. Twenty microliters of cell suspension (500 cells per 20 ml) were seeded on the siRNA plate and the plates were main-
tained in culture for 96 h. The viability of cells after siRNA treatments was assessed with CellTiter-Glo (Promega). The luminescencee2 Cell Chemical Biology 26, 1–10.e1–e4, July 18, 2019
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Selective Therapeutic Targets, Cell Chemical Biology (2019), https://doi.org/10.1016/j.chembiol.2019.03.011measurements were converted to percent inhibition compared to the positive and negative controls. The siRNAs screens were per-
formed in 5 technical replicates and their effects were evaluated as mean±SME.
Target Deconvolution Analysis
Target deconvolution analysis was performed as previously described (Al-Ali et al., 2015). Briefly, cell-based activities, expressed
as DSS (Yadav et al., 2014) (Table S5), were used to stratify compounds into one of two classes: hits (DSS R 5) and non-hits
(DSS % 0.5). Kinase activity profiles for the stratified compounds were acquired from previously published datasets (Al-Ali
et al., 2015; Anastassiadis et al., 2011; Arrowsmith et al., 2015; Davis et al., 2011; Drewry et al., 2014, 2017), and integrated
with additional activity data obtained from PubChem and ChEMBL (https://doi.org/10.6019/CHEMBL1961873). In total, 200
non-mutant kinases were included in the analysis. The mutual information for each kinase within the compound classes was calcu-
lated and used to prioritize a subset of potentially relevant target kinases for each cell line (maximum relevance algorithm, MR, (Al-
Ali et al., 2015)) A rule-based selection algorithm using vector machine (SVM) was then used to identify the smallest number of
kinases that can predict the hit class of compounds (maximum information set, MAXIS, (Al-Ali et al., 2015)). This analysis was per-
formed 100 times, each time using a different combination of hits and non-hits as the starting set (90% of total, randomly selected,
with hits to non-hits ratios preserved). The overall scheme is abbreviated as MR-SVM. In the end, each kinase received a MAXIS
score ranging between 0 and 100, reflective of how many times it was selected by the algorithm into MAXIS over the 100 runs. The
inhibition bias of each kinase (Bk) by the hits or the non-hits was also quantified using the metric previously described in (Al-Ali
et al., 2015). A positive Bk (more inhibition by hits) value suggests that the kinase is a target (inhibition results in the cell viability
inhibition), while a negative Bk (more inhibition by non-hits) suggests that the kinase is an anti-target (inhibition results in cell pro-
liferation). The product of MAXIS score and Bk constituted the combined score for every kinase for each cell line. A scaling func-
tion was used to adjust combined kinase scores to a range of [-100, +100] and to de-emphasize the scores for low inhibition bias
(i.e. to emphasize kinases whose inhibition shows high correlation with cellular outcome). Finally, kinases that have high likelihood
of being co-inhibited by the same compounds were grouped into pharmacologically linked groups as previously described (Al-Ali
et al., 2015). The MAXIS score and Bk for the groups were calculated as the means of the MAXIS scores and Bks (Table S7) of the
individual kinase members, respectively. The combined MAXIS*Bk scores were then used to rank order the groups. The whole
process is termed idTRAX (Identification of Drug TaRgets and Anti-targets by Cellular and Molecular Cross-referencing). A high
positive MAXIS*Bk score indicates that a group contains one or more targets, while a low negative score indicates that a group
contains one or more anti-targets. In this study, we used an implementation of idTRAX generated by Truvitech LLC through a
collaboration with the company, though the method can also be recreated from the methods described in Al Ali et al. (2015)
(Al-Ali et al., 2015).
Published DataSets and Analysis
siRNA Screening Dataset
Campbell et al. (Campbell et al., 2016) performed a kinome-wide plate-array based siRNA screening on a compendium of 115 cancer
cell lines to quantify the effect of inhibition of each kinase on the proliferation. Robust z-scores estimating the dependency of
each kinase in breast cancer cell lines was extracted from this dataset. Eleven cell lines used in our study were common to
Campbell et al. study; BT-474, BT-549, CAL-120, CAL-51, DU4475, Hs578T, MDA-MB-231, MDA-MB-436, MDA-MB-453, MFM-
223, SK-BR-3.
shRNA Screening Dataset
Marcotte et al. (Marcotte et al., 2016) performed a genome-wide shRNA screen on 77 breast cancer cell lines to estimate the
dependency of each gene for cell proliferation. Z-scaled Gene Activity Rank Profile (z-GARP scores) of the kinases overlapping
with Campbell et al. were extracted from this dataset for comparison. All 19 cell lines used in our study were also shRNA-profiled
in the Marcotte et al. study.
CRISPR Screening Dataset
Meyers et al. (Meyers et al., 2017) performed a genome-wide CRISPR knockout screen on 342 cancer cell lines and applied
the CERES algorithm to quantify the gene dependency scores. We extracted the dependency scores for all kinases
that were overlapping with the Campbell et al. dataset. Eleven cell lines used in our study were common to Meyers
et al. study; BT-549, CAL-51, DU4475, HCC1143, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-
MB-468, SK-BR-3.
Analysis Methods
For comparison of the gene dependency scores from each data type, we extracted the data for breast cancer cell lines that were
commonly profiled between the aforementioned datasets and restricted the analysis to the kinases which were shared across the
all the datasets (Table S8). Spearman rank correlation between the overlapping datasets was calculated for estimating the strength
of agreement between each data type. MAXIS*Bk scores were reversed to match the direction of the siRNA, shRNA and CRISPR
scores.Cell Chemical Biology 26, 1–10.e1–e4, July 18, 2019 e3
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All the dose-response curves, bar plots and scatter plots were made with GraphPad Prism software and subsequent statistical
analysis was also carried out using the same software. One-way ANOVA was performed to test the effect of siRNAs, and Dunnett’s
multiple comparison test was performed to evaluate the statistical significance.
DATA AND SOFTWARE AVAILABILITY
All normalized drug screening data is available in Tables S5 and S6. All MAXIS*BK scores for the 198 kinases evaluated in the study
are listed in Table S7. For calculation of MAXIS*BK scores, we used an implementation of idTRAX generated by Truvitech LLC
through a collaboration with the company.e4 Cell Chemical Biology 26, 1–10.e1–e4, July 18, 2019
